Search
forLearn
5 / 801 resultslearn TDM-105795
learn PTD-DBM
learn TeraCeutic™
learn PTT-6®
Research
5 / 1000+ resultsresearch Activation and regulation of the granulation tissue derived cells with stemness-related properties
Granulation tissue-derived cells can aid wound healing and serve as an alternative source of stem cells for tissue repair.
research Hair loss with levetiracetam in five patients with epilepsy
Levetiracetam may cause hair loss, which can potentially reverse with lower doses or stopping the drug.
research Ultrastructural and immunohistochemical characteristics of telocytes in human scalp tissue
Telocytes in the scalp may help with skin regeneration and maintenance.
research Levetiracetam in the Treatment of Idiopathic Generalized Epilepsies
Levetiracetam is widely used and generally well-tolerated for treating idiopathic generalized epilepsies, with tiredness as the main side effect.
research Valproate-Associated Transaminitis and Rhabdomyolysis
Valproic acid can cause muscle damage and liver issues, which improve after stopping the drug.
Community Join
5 / 1000+ resultscommunity GT20029 Big Phase 2 Update Results!
GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.
community Where is GT20029 already? Grrrr
The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.
community Looks like Kintor finished enrollment and dosing of phase 1 for gt20029 in China.
The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.
community GT20029 - Stand-alone Saviour or just part of the stack?
The post discusses the potential of GT20029 in treating hair loss, questioning if it will replace finasteride or be used alongside existing treatments. A reply indicates that its role is still uncertain.
community GT20029 - Promising phase II results
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.